Bazan Jose, DiCostanzo Dominic, Kuhn Karla, Majithia Lonika, Quick Allison, Gupta Nilendu, White Julia
Department of Radiation Oncology, Ohio State University, Columbus, Ohio.
Department of Radiation Oncology, Ohio State University, Columbus, Ohio.
Pract Radiat Oncol. 2017 May-Jun;7(3):154-160. doi: 10.1016/j.prro.2016.10.012. Epub 2016 Oct 19.
As indications for regional nodal irradiation (RNI) for breast cancer have expanded, so too has scrutiny over potential late toxicity from radiotherapy. This emphasizes the need for careful radiation treatment planning to maximize the therapeutic ratio. We sought to evaluate how often unacceptable doses (UDs) to organs at risk (OARs) occur and the associated factors for patients receiving RNI in daily practice.
Treatment records of patients who received RNI from February 2012 to May 2015 were studied. The NSABP B51/RTOG 1304 clinical dose-volume constraints for targets/OARs receiving RNI were used as the benchmark. Dose-volume histograms were analyzed for the rate of ≥1 UD delivered to the following organs: heart, mean >5 Gy; ipsilateral lung, V20 >35%, V10 >60%, V5 >70%; contralateral lung (CL), V5 >15%; and contralateral breast, V4.1 >5%. Logistic regression was used to test the association between UDs to OAR and key variables.
Two hundred three consecutive cases received RNI (105 left, 98 right), to the chest wall in 171 (84%) and to the internal mammary nodes in 170 (84%); 77.4% of cases met all OAR constraints. The most common OAR UDs were delivered to the contralateral breast (n = 32, 15.7%) and ipsilateral lung V5 (n = 22, 10.8%). On multivariate analysis, use of intensity modulated radiation therapy (odds ratio [OR], 64.7; 95% confidence interval, 20.8-201.5; P < .001) and use of nodal boost (OR, 5.5; 95% confidence interval, 1.1-27.1; P = .04), but not internal mammary node irradiation (OR, 2.7; P = .35) or reconstruction (OR, 0.62; P = .33), were independently associated with higher OAR UD rate. For 3-dimensional conformal radiation therapy plans, 7.9% had OAR UDs.
The OAR UD rate with 3-dimensional conformal radiation therapy ± deep inspiration breath-hold in routine clinical practice is low and not independently associated with internal mammary node irradiation or reconstruction presence. Women treated with intensity modulated radiation therapy had a significantly higher overall OAR UD rate, and clinicians should be aware of this as they initiate RNI treatment planning.
随着乳腺癌区域淋巴结照射(RNI)适应证的扩大,对放疗潜在晚期毒性的审查也在增加。这凸显了精心制定放射治疗计划以最大化治疗比的必要性。我们试图评估在日常实践中接受RNI的患者发生危及器官(OAR)不可接受剂量(UD)的频率及其相关因素。
研究了2012年2月至2015年5月接受RNI的患者的治疗记录。将接受RNI的靶区/OAR的NSABP B51/RTOG 1304临床剂量-体积限制作为基准。分析剂量-体积直方图,以确定以下器官接受≥1次UD的发生率:心脏,平均>5 Gy;同侧肺,V20>35%,V10>60%,V5>70%;对侧肺(CL),V5>15%;以及对侧乳腺,V4.1>5%。使用逻辑回归检验OAR的UD与关键变量之间的关联。
连续203例患者接受了RNI(左侧105例,右侧98例),171例(84%)照射胸壁,170例(84%)照射内乳淋巴结;77.4%的病例符合所有OAR限制。最常见的OAR的UD发生在对侧乳腺(n = 32,15.7%)和同侧肺V5(n = 22,10.8%)。多因素分析显示,使用调强放射治疗(优势比[OR],64.7;95%置信区间,20.8 - 201.5;P <.001)和使用淋巴结推量(OR,5.5;95%置信区间,1.1 - 27.1;P =.04),而非内乳淋巴结照射(OR,2.7;P =.35)或重建(OR,0.62;P =.33),与更高的OAR的UD发生率独立相关。对于三维适形放射治疗计划,7.9%存在OAR的UD。
在常规临床实践中,三维适形放射治疗±深吸气屏气时OAR的UD发生率较低,且与内乳淋巴结照射或重建的存在无独立关联。接受调强放射治疗的女性总体OAR的UD发生率显著更高,临床医生在开始RNI治疗计划时应意识到这一点。